A biologics license issued to a manufacturer and covering all locations of manufacture shall authorize persons other than such manufacturer to conduct at places other than such locations the initial, and partial manufacturing of a product for shipment solely to such manufacturer only to the extent that the names of such persons and places are registered with the Commissioner of Food and Drugs and it is found upon application of such manufacturer, that the product is in short supply due either to the peculiar growth requirements of the organism involved or to the scarcity of the animal required for manufacturing purposes, and such manufacturer has established with respect to such persons and places such procedures, inspections, tests or other arrangements as will ensure full compliance with the applicable regulations of this subchapter related to continued safety, purity, and potency. Such persons and places shall be subject to all regulations of this subchapter except §§ 601.2 to 601.6 , 601.9 , 601.10 , 601.20 , 601.21 to 601.33 , and 610.60 to 610.65 of this chapter . For persons and places authorized under this section to conduct the initial and partial manufacturing of a product for shipment solely to a manufacturer of a product subject to licensure under § 601.2(c) , the following additional regulations shall not be applicable: §§ 600.10(b) and (c) , 600.11 , 600.12 , 600.13 , and 610.53 of this chapter . Failure of such manufacturer to maintain such procedures, inspections, tests, or other arrangements, or failure of any person conducting such partial manufacturing to comply with applicable regulations shall constitute a ground for suspension or revocation of the authority conferred pursuant to this section on the same basis as provided in §§ 601.6 to 601.8 with respect to the suspension and the revocation of licenses.
21 CFR Part 601 · Licensing
§ 601.22 Products in short supply; initial manufacturing at other than licensed location
Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.
FDA guidance that cites § 601.22
- Cooperative Manufacturing Arrangements for Licensed Biologics: Guidance for Industry 28 Nov 2008
- FDA Recommendations Concerning Testing for Antibody to Hepatitis B Core Antigen (Anti-HBc) 10 Sept 1991
Amendment history
Federal Register documents that created or amended this section.
- 42 FR 4718 25 Jan 1977
- 61 FR 24233 14 May 1996
- 64 FR 56452 20 Oct 1999
- 80 FR 37974 2 Jul 2015